Skip to content

Study · Case report or series · n = 4 · 2025

4 results

Allodynia (skin tenderness) associated with semaglutide: A case series.

Stark J, Klass MJ, Owen L

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists1 Apr 2025Cited by 6 (Europe PMC)

PMID39862389 (opens in a new tab)DOI10.1093/ajhp/zxaf008 (opens in a new tab)PepBankPUB-39862389
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In four adults with obesity, allodynia developed during semaglutide dose escalation to 2.4 mg weekly.

    In plain wordsIn four adults with obesity, skin pain to the touch appeared while the semaglutide dose was raised.

    Peptide
    Semaglutide
    Outcome
    IncreaseAllodynia (skin tenderness)
    Study

    n = 4

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We report 4 cases of allodynia associated with dose escalation of the GLP-1RA medication semaglutide.
    1 context sentence
    Summary · context
    Each patient was prescribed semaglutide for management of obesity and developed symptoms of allodynia with the 2.4-mg subcutaneous once-weekly dose.
  2. 02HumanCase report or seriesSafety outcome

    In each of the four cases, allodynia showed a clear temporal and dose-response relationship with semaglutide.

    In plain wordsIn all four cases, skin pain appeared after semaglutide started and with higher doses.

    Peptide
    Semaglutide
    Outcome
    IncreaseDose-response relationship of allodynia
    Study

    n = 4

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There was a clear temporal and dose-response relationship in each of the 4 cases.
    1 context sentence
    Summary · context
    Each patient was prescribed semaglutide for management of obesity and developed symptoms of allodynia with the 2.4-mg subcutaneous once-weekly dose.
  3. 03HumanCase report or seriesSafety outcome

    Allodynia resolved in both patients who stopped semaglutide; of two who continued, one had resolution after 4 months.

    In plain wordsSkin pain went away in both patients who stopped semaglutide, and in one of two who continued it.

    Peptide
    Semaglutide
    Outcome
    MixedResolution of allodynia after stopping or continuing
    Study

    n = 4

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Therapy was stopped in 2 patients, both of whom had resolution of symptoms. Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.
    1 context sentence
    Summary · context
    Each patient was prescribed semaglutide for management of obesity and developed symptoms of allodynia with the 2.4-mg subcutaneous once-weekly dose.
  4. 04HumanCase report or seriesSafety outcome

    The four allodynia cases scored 5 or 6 (probable) on the Naranjo scale for adverse drug reactions.

    In plain wordsA standard causality scale rated the link between semaglutide and skin pain as probable in all four cases.

    Peptide
    Semaglutide
    Outcome
    Not applicableNaranjo causality score
    Study

    n = 4

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Naranjo score
    5 to 6 points
    4 cases

    Source sentences

    Summary
    The 4 cases presented had scores of 5 or 6 (probable) on the Naranjo scale.
    1 context sentence
    Summary · context
    Each patient was prescribed semaglutide for management of obesity and developed symptoms of allodynia with the 2.4-mg subcutaneous once-weekly dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.